Skip to content

ImmunityBio, Inc.

IBRX· NasdaqCore metricsCIK 1326110

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -9.00%
Market cap
$6.45B
1.06B shares
Filings
557
$48.84M
Q3 2026+668.3% FY25 yoy
-$184.55M
Q3 2026N/M FY25 yoy
-$77.99M
Q3 2026N/M FY25 yoy
-$225.41M
Q3 2026derivedN/M FY25 yoy
-$0.18
Q3 2026N/M FY25 yoy
$45.08M
Q3 2026−38.4% FY25 yoy
$6.45B
—
35.3×
—
-4.60%
—

Twelve months to Sep 30, 2026 · derived

Price

$6.07+183.41%+$3.93past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$113.29MFY 2025
$113.29M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$113,288,000reported
FY 20242024-12-31$14,745,000reported
FY 20232023-12-31$622,000reported
FY 20222022-12-31$240,000reported
FY 20212021-12-31$934,000reported
FY 20202020-12-31$605,000 revisedreported
FY 20192019-12-31$2,202,000 revisedreported
FY 20182018-12-31$47,000reported
FY 20172017-12-31$45,000reported
FY 20162016-12-31$44,000reported
FY 20152015-12-31$236,000reported
FY 20142014-12-31$641,000reported

Capital returns

Dividends and buybacks · FY2014 to FY2021
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2021—$0.00$0.00—397.91M sh+263.9%—
FY2020—$0.00$0.00—109.34M sh+11.0%—
FY2019—$2.50M$2.50M—98.48M sh+24.5%—
FY2018—$228.00K$228.00K—79.09M sh+0.1%—
FY2017—$15.23M$15.23M—79.03M sh−4.0%—

Segments

Revenue by Geography, FY2019 to FY2025FY2019U.S. · FY2019 · $2.00MEurope · FY2019 · $205.00KFY2020U.S. · FY2020 · $513.00KEurope · FY2020 · $92.00KFY2021U.S. · FY2021 · $373.00KEurope · FY2021 · $561.00KFY2022U.S. · FY2022 · $42.00KEurope · FY2022 · $198.00KFY2023U.S. · FY2023 · $31.00KEurope · FY2023 · $591.00KFY2024U.S. · FY2024 · $14.21MEurope · FY2024 · $531.00KFY2025U.S. · FY2025 · $113.01MEurope · FY2025 · $278.00K
LineFY2025ShareChange
U.S.$113.01M100%+695.1%
Europe$278.00K0.2%−47.6%
Total$113.29M

From the 10-K filed Feb 23, 2026IBRX

Biological products, except diagnostic substances

ImmunityBio, Inc. is the 29th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

ImmunityBio, Inc. · CIK 1326110 · Engraved from SEC EDGAR